A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

Introduction/Aims: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC-NTF), a novel autologous cell-therapy capable of targeting multip...

Full description

Bibliographic Details
Main Authors: Aricha, R. (Author), Baloh, R.H (Author), Berry, D.A (Author), Berry, J.D (Author), Brown, R.H., Jr (Author), Burford, M.J (Author), Cudkowicz, M.E (Author), Gothelf, Y. (Author), Goyal, N.A (Author), Jenkins, L.J (Author), Katz, J.S (Author), Kern, R.Z (Author), Levy, Y.S (Author), Lewis, R.A (Author), Lindborg, S.R (Author), Miller, R.G (Author), Mozaffar, T. (Author), Nicholson, K.A (Author), Owegi, M.A (Author), Staff, N.P (Author), Windebank, A.J (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2022
Subjects:
adult
ALSFRS-R
amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
Article
autotransplantation
biological marker
biomarker
clinical effectiveness
clinical trial
controlled study
double blind procedure
Double-Blind Method
female
human
human cell
Humans
major clinical study
male
mesenchymal stem cell
mesenchymal stem cell transplantation
Mesenchymal Stem Cells
metabolism
multicenter study
nerve growth factor
Nerve Growth Factors
neurotrophic factor
pain
parallel design
patient safety
phase 3 clinical trial
placebo
randomized controlled trial
riluzole
stem cells
Transplantation, Autologous
treatment response
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items